Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL)

Cancer

Volumn 120, Issue 23, 2014, Pages 3660-3668

  Rytting, Michael E ^a   Thomas, Deborah A ^a   O'Brien, Susan M ^a   Ravandi Kashani, Farhad ^a   Jabbour, Elias J ^a   Franklin, Anna R ^a   Kadia, Tapan M ^a   Pemmaraju, Naveen ^a   Daver, Naval G ^a   Ferrajoli, Alessandra ^a   Garcia Manero, Guillermo ^a   Konopleva, Marina Y ^a   Cortes, Jorge E ^a   Borthakur, Gautham ^a   Garris, Rebecca ^a   Cardenas Turanzas, Maria ^a   Schroeder, Kurt ^a   Jorgensen, Jeffrey L ^a   Kornblau, Steven M ^a   Kantarjian, Hagop M ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Acute lymphoblastic leukemia; Augmented Berlin Frankfurt Munster; Pediatric based regimens; Pediatric based therapy; Philadelphia chromosome negative ALL

Indexed keywords

ASPARAGINASE MACROGOL; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; TIOGUANINE; VINCRISTINE; ANTINEOPLASTIC AGENT; ASPARAGINASE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; AUGMENTED BERLIN FRANKFURT MUNSTER THERAPY; BONE NECROSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER THERAPY; CHILD; CONTROLLED STUDY; DRUG RESPONSE; DRUG TOLERABILITY; EVENING DOSAGE; FEMALE; HUMAN; LEUKEMIA REMISSION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREATITIS; PHILADELPHIA CHROMOSOME NEGATIVE CELL; REPEATED DRUG DOSE; SCHOOL CHILD; THROMBOSIS; YOUNG ADULT; COHORT ANALYSIS; CONSOLIDATION CHEMOTHERAPY; INDUCTION CHEMOTHERAPY; MAINTENANCE CHEMOTHERAPY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROSPECTIVE STUDY; TREATMENT OUTCOME;

6-MERCAPTOPURINE; ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; COHORT STUDIES; CONSOLIDATION CHEMOTHERAPY; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; FEMALE; HUMANS; INDUCTION CHEMOTHERAPY; MAINTENANCE CHEMOTHERAPY; MALE; METHOTREXATE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROSPECTIVE STUDIES; THIOGUANINE; TREATMENT OUTCOME; VINCRISTINE; YOUNG ADULT;

EID: 84907846523     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28930     Document Type: Article

References (41)

1. Stock W, La M, Sanford B., et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood. 2008; 112:1646-1654.
2. Boissel N, Auclerc MF, Lheritier V, et al. Should adolescents with acute lymphoblastic leukemia be treated as old children of young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol. 2003; 21:774-780.
3. Ramanujachar R, Richards S, Hans I., et al. Adolescents with acute lymphoblastic leukaemia: outcome on UK national paediatric (ALL97) and adult (UKALLXII/E2993) trials. Pediatr Blood Cancer. 2007; 48:254-261.
4. Ram R, Wolach O, Vidal L., et al. Adolescents and young adults with acute lymphoblastic leukemia have a better outcome when treated with pediatric-inspired regimens: systematic review and meta-analysis. Am J Hematol. 2012; 87:472-478.
5. Usvasalo A, Raty R, Knuutila S., et al. Acute lymphoblastic leukemia in adolescents and young adults in Finland. Haematologica. 2008; 93: 1161-1168.
6. Ribera JM, Oriol A, Sanz M.A., et al. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Trata-miento en Hematologia pediatric-based protocol ALL-96. J Clin Oncol. 2008; 26:1843-1849.
7. Huguet F, Leguay T, Raffoux E., et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative ALL: the GRAALL-2003 study. J Clin Oncol. 2009; 27:911-918.
8. Lukenbill J, Advani AS. The treatment of adolescents and young adults with acute lymphoblastic leukemia. Curr Hematol Malig Rep. 2013; 8:91-97.
9. Nachman J, La MK, Hunger S.P., et al. Young adults with acute lym-phoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the Children's Oncology Group. J Clin Oncol. 2009; 27:5189-5194.
10. Seibel NL, Steinherz PG, Sather S.N., et al. Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 2008; 111:2548-2555.
11. Pui C, Howard S. Current management and challenges of malignant disease in the CNS in paediatric leukaemia. Lancet Oncol. 2008; 9:257-268.
12. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53:457-481.
13. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966; 50:163-170.
14. Cox DR. Regression models and life tables. J R Stat Soc B. 1972; 34: 187-220.
15. Thomas D, O'Brien S, Faderl S, et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol. 2014; 28:3880-3889.
16. Kurtsberg J, Asselin B, Bernstein M., et al. Polyethylene glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a Children's Oncology Group study (POG 8866). J Pediatr Hematol Oncol. 2011; 33:610-616.
17. Kantarjian H, Thomas D, O'Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 2004; 101:2788-2801.
18. Pullen J, Shuster J, Link M., et al. Significance of commonly used prognostic factors differs for children with T cell acute lymphocytic leukemia (ALL), as compared to those with B-precursor ALL. A Pediatric Oncology Group (POG) study. Leukemia. 1999; 13:1696-1707.
19. Van Dongen JJ, Seriu T, Panzer-Grumayer ER, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet. 1998; 352:1731-1738.
20. Jacquy C, Delepaut B, Van Daele S, et al. A prospective study of minimal residual disease in childhood B-lineage acute lymphoblastic leukaemia. Br J Hematol. 1997; 98:140-146.
21. Conter V, Bartram CR, Valsecchi M.G., et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia. Blood. 2010; 115:3206-3214.
22. Borowitz MJ, Devidas M, Hunger S.P., et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors. A Children's Oncology Group study. Blood. 2008; 111:5477-5485.
23. Dworzak MN, Froschl G, Printz D., et al. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood. 2002; 99:1952-1958.
24. Basso G, Veltroni M, Valsecchi M.G., et al. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow. J Clin Oncol. 2002; 27:5168-5174.
25. Coustan-Smith E, Sancho J, Hancock M.L., et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood. 2000; 96:2691-2696.
26. Bassan R, Spinalli O, Oldani E., et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood. 2009; 113:4153-4162.
27. Nagafuji K, Mayamoto T, Eto T., et al. Monitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Phnegative ALL: results of a prospective study (ALL MRD 2002 Study) [serial online]. J Hematol Oncol. 2013; 6:14.
28. Gokbuget N, Kneba M, Raff T., et al. Adult patients with acute lym-phoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood. 2012; 120:1868-1876.
29. Prucker C, Attarbaschi A, Peters C., et al. Induction death and treatment related mortality in first remission of children with acute lym-phoblastic leukemia. Leukemia. 2009; 23:1264-1269.
30. Rubnitz J, Lensing S, Zhou Y., et al. Death during induction therapy and first remission of acute leukemia in childhood. Cancer. 2004; 101:1677-1684.
31. Mattano LA Jr, Sather HN, Trigg M.E., Nachman JB. Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children's Cancer Group. J Clin Oncol. 2000; 18:3262-3272.
32. te Winkel ML, Pieters R, Hop W.C., et al. Prospective study on incidence, risk factors, and long-term outcome of osteonecrosis in pedi-atric acute lymphoblastic leukemia. J Clin Oncol. 2011; 29:4143-4150.
33. Nowak-Gottl U, Ahlke I, Fleischhack G., et al. Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administration. Blood. 2003; 101:2529-2533.
34. Lancaster D, Lennard L, Lilleyman JS. Profile of non-compliance in lymphoblastic leukaemia. Arch Dis Child. 1997; 76:365-366.
35. Pritchard MT, Butow P, Stevens M., et al. Understanding medication adherence in pediatric acute lymphoblastic leukemia: a review. J Pediatr Hematol Oncol. 2006; 28:816-823.
36. Marin D, Bazeos A, Mahon F.X., et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010; 28:2381-2388.
37. Festas RS, Tamaroff MH, Chasalow F, et al. Therapeutic adherence to oral medication regimens by adolescents with cancer. I. Laboratory assessment. J Pediatr. 1992; 120:807-811.
38. Bhatia S, Landier W, Shangguan M., et al. Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic leukemia: a report from the Children's Oncology Group. J Clin Oncol. 2012; 30:2094-2101.
39. Barry E, DeAngelo DA, Neuberg D, et al. Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium protocols. J Clin Oncol. 2007; 25:813-819.
40. Panosyan E, Seibel NL, Martin-Aragon S, et al. Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961. J Pediatr Hematol Oncol. 2004; 26:217-226.
41. Raja RA, Schmiegelow K, Frandsen TL. Asparaginase-associated pancreatitis in children. Br J Haematol. 2012; 159:18-27.